Rock Point Advisors LLC continued to hold its stake in Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,026 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Rock Point Advisors LLC’s holdings in Celgene Corporation were worth $263,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of CELG. Toronto Dominion Bank boosted its position in shares of Celgene Corporation by 22.6% during the 1st quarter. Toronto Dominion Bank now owns 413,342 shares of the biopharmaceutical company’s stock worth $51,426,000 after purchasing an additional 76,322 shares in the last quarter. Eagle Asset Management Inc. boosted its position in shares of Celgene Corporation by 1.5% during the 1st quarter. Eagle Asset Management Inc. now owns 20,128 shares of the biopharmaceutical company’s stock worth $2,504,000 after purchasing an additional 295 shares in the last quarter. Warren Averett Asset Management LLC bought a new position in shares of Celgene Corporation during the 1st quarter worth about $438,000. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Celgene Corporation during the 1st quarter worth about $118,000. Finally, Sawtooth Solutions LLC boosted its position in shares of Celgene Corporation by 19.8% during the 1st quarter. Sawtooth Solutions LLC now owns 8,307 shares of the biopharmaceutical company’s stock worth $1,034,000 after purchasing an additional 1,375 shares in the last quarter. 79.48% of the stock is currently owned by institutional investors and hedge funds.

Celgene Corporation (NASDAQ:CELG) opened at $104.10 on Monday. The company has a market cap of $81,959.70, a P/E ratio of 16.27, a P/E/G ratio of 0.80 and a beta of 1.79. Celgene Corporation has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period last year, the firm earned $1.58 EPS. Celgene Corporation’s revenue for the quarter was up 10.2% on a year-over-year basis. analysts predict that Celgene Corporation will post 6.67 earnings per share for the current year.

In other Celgene Corporation news, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total value of $1,286,027.50. Following the completion of the transaction, the director now directly owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,227 shares of company stock valued at $2,843,956. Insiders own 0.95% of the company’s stock.

CELG has been the topic of a number of research analyst reports. Vetr cut shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective on the stock. in a research report on Tuesday, August 29th. Royal Bank Of Canada cut their price objective on shares of Celgene Corporation from $166.00 to $148.00 and set a “top pick” rating on the stock in a research report on Friday, October 27th. Leerink Swann reissued a “buy” rating and set a $156.00 price objective on shares of Celgene Corporation in a research report on Friday, October 20th. Morgan Stanley cut their price objective on shares of Celgene Corporation from $120.00 to $115.00 and set an “underweight” rating on the stock in a research report on Monday, October 23rd. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Celgene Corporation in a research report on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company. Celgene Corporation currently has an average rating of “Buy” and an average target price of $139.87.

WARNING: “Rock Point Advisors LLC Has $263,000 Stake in Celgene Corporation (CELG)” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/rock-point-advisors-llc-has-263000-stake-in-celgene-corporation-celg/1715081.html.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.